

MERIDIAN BIOSCIENCE INC  
 Form S-8  
 February 04, 2005

As filed with the Securities and Exchange Commission on February 4, 2005  
 Registration No. 333-

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM S-8**  
**REGISTRATION STATEMENT**  
**UNDER**  
**THE SECURITIES ACT OF 1933**

**MERIDIAN BIOSCIENCE, INC.**

(Exact name of Registrant as Specified in its Charter)

<p><b>Ohio</b></p> <p>(State Or Other Jurisdiction Of                  Incorporation Or Organization)</p>	<p><b>3471 River Hills Drive</b>  <b>Cincinnati, Ohio 45244</b>  <b>(513) 271-3700</b></p> <p>(Address, including zip code, and telephone                  number, including area code, of registrant's                  principal executive offices)</p>	<p><b>31-0888197</b></p> <p>(IRS Employer                  Identification Number)</p>
---	---	---

**2004 EQUITY COMPENSATION PLAN**

(Full Title of the Plan)

Mark A. Weiss, Esq.  
 Keating, Muething & Klekamp, P.L.L.  
 1400 Provident Tower  
 One East Fourth Street  
 Cincinnati, Ohio 45202  
 Telephone: (513) 579-6599  
 Facsimile: (513) 579-6457

(Name, Address and Telephone Number of Agent for Service)

**CALCULATION OF REGISTRATION FEE**

Title of Securities To Be Registered	Amount To Be Registered(1)	Proposed Maximum Offering Price Per Share	Proposed Maximum Aggregate Offering Price	Amount of Registration Fee(3)
Common Stock	650,000 Shares	\$15.13(2)	\$9,834,500(2)	\$1,246.03

(1) In addition, pursuant to Rule 416(c) under the Securities Act of 1933, this registration statement also covers an indeterminate amount of interests to be offered or sold pursuant to the 2004 Equity Compensatin Plan.

- (2) Estimated to calculate registration fee.
- (3) Calculated pursuant to Rule 457(h) based on the average of the high and low prices of the Common Stock on the Nasdaq National Market on January 28, 2005 of \$15.13 per share.

---

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference**

The following documents filed by Meridian Bioscience, Inc. with the Securities and Exchange Commission are incorporated herein by reference and made a part hereof:

1. Meridian's Annual Report on Form 10-K for the fiscal year ended September 30, 2004.
2. Meridian's Current Reports on Form 8-K filed on November 23, 2004, December 13, 2004, December 14, 2004 and January 25, 2005 and on Form 8-K/A filed on December 23, 2004.
3. The description of the Common Stock contained in the Registration Statement on Form 8-A filed on August 15, 1986 and amended August 20, 1986 registering Meridian's Common Stock under Section 12 of the Securities Exchange Act of 1934.

All reports and other documents subsequently filed by Meridian pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, prior to the filing of a post-effective amendment which indicates that all Common Stock offered has been sold or which deregisters all Common Stock then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing such documents.

**Item 4. Description of Securities**

Not Applicable.

**Item 5. Interests of Named Experts and Counsel**

Not Applicable.

**Item 6. Indemnification of Directors and Officers**

Ohio Revised Code, Section 1701.13(E), allows indemnification by the registrant to any person made or threatened to be made a party to any proceedings, other than a proceeding by or in the right of the registrant, by reason of the fact that he is or was a director, officer, employee or agent of the registrant, against expenses, including judgment and fines, if he acted in good faith and in a manner reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to criminal actions, in which he had no reasonable cause to believe that his conduct was unlawful. Similar provisions apply to actions brought by or in the right of the registrant, except that no indemnification shall be made in such cases when the person shall have been adjudged to be liable for negligence or misconduct to the registrant unless deemed otherwise by the court. Indemnification is to be made by a majority vote of a quorum of disinterested directors or the written opinion of independent counsel or by the shareholders or by the court. The registrant's Code of Regulations extends such indemnification.

The foregoing discussion is subject to the complete text of Section 1701.13(E) and is qualified in its entirety by reference thereto.

**Item 7. Exemption from Registration Claimed**

Not Applicable.

**Item 8. Exhibits**

- |              |  |
|--------------|--|
| Exhibit 4    | 2004 Equity Compensation Plan, as amended (incorporated by reference Appendix A to Meridian's Proxy Statement filed December 23, 2004) |
| Exhibit 5    | Opinion of Keating, Muething & Klekamp, P.L.L.   |
| Exhibit 23.1 | Consent of PricewaterhouseCoopers LLP  |
| Exhibit 23.2 | Consent of Keating, Muething & Klekamp, P.L.L. (included in Exhibit 5)   |
| Exhibit 24   | Power of Attorney (contained in the signature page)  |
- \* All Exhibits filed herewith unless otherwise indicated

**Item 9. Undertakings**

9.1 The undersigned registrant hereby undertakes to file during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement: (i) to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; (ii) to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the Calculation of Registration Fee table in the effective Registration Statement; (iii) to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; provided, however, that (i) and (ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Registration Statement.

9.2 The undersigned registrant hereby undertakes that, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

9.3 The undersigned registrant hereby undertakes to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

9.4 The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

9.5 Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Cincinnati, Ohio, on February 4, 2005.



Edgar Filing: MERIDIAN BIOSCIENCE INC - Form S-8

Ladies and Gentlemen:

This firm is general counsel to Meridian Bioscience, Inc. and as such, we are familiar with Meridian's Articles of Incorporation, Code of Regulations and corporate proceedings generally. We have reviewed the corporate records as to the 2004 Equity Compensation Plan (the "Plan"), pursuant to which a total of 650,000 shares of Common Stock may be issued. Based solely upon such examination, we are of the opinion that Meridian has taken all necessary and required corporate actions in connection with the proposed issuance of up to an additional 650,000 shares of Common Stock pursuant to the Plan, and the Common Stock, when issued, delivered and paid for under the terms of the Plan, will be validly issued, fully paid and non-assessable shares of Common Stock of Meridian free of any claim of pre-emptive rights.

We hereby consent to be named in the Registration Statement and the Prospectus part thereof as the attorneys who have passed upon legal matters in connection with the issuance of the aforesaid Common Stock and to the filing of this opinion as an exhibit to the Registration Statement.

Very truly yours,

KEATING, MUETHING & KLEKAMP, P.L.L.

BY: /s/ Mark A. Weiss  
Mark A. Weiss

---

**EXHIBIT 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated November 12, 2004 relating to the financial statements and financial statement schedule of Meridian Bioscience, Inc., which appears in Meridian Bioscience, Inc.'s Annual Report on Form 10-K for the year ended September 30, 2004.

/s/ PricewaterhouseCoopers LLP

Cincinnati, Ohio

January 31, 2005